GlassScriptPhysician profile
Kendra Maxey
NPI 1285411603
$3,624.71
in general payments reported to CMS, 2019-2025
24 companies · $1,729 in 2025
The $1,729 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $418 · 2024: $1,477 · 2025: $1,729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,625.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,624.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $482.57 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $458.18 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $423.86 | 2023-2025 | Rexulti |
| Novo Nordisk INC | $331.35 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $327.86 | 2023-2025 | |
| Pfizer INC. | $302.87 | 2024-2025 | |
| Amgen INC. | $227.76 | 2023-2025 | Otezla, Repatha, Repatha |
| Exact Sciences Corporation | $126.52 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lundbeck LLC | $119.62 | 2024-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.15 | 2024-2025 | Jardiance, Tradjenta |
| Merck Sharp & Dohme LLC | $100.19 | 2023-2024 | Verquvo, Belsomra |
| Sumitomo Pharma America, INC. | $100.11 | 2024-2025 | Gemtesa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $85.71 | 2024-2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $84.02 | 2023-2025 | |
| Axsome Therapeutics, INC. | $53.30 | 2023-2025 | Auvelity |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $45.83 | 2025 | Yupelri |
| Kowa Pharmaceuticals America, INC. | $44.00 | 2024-2025 | Zoryve |
| Janssen Pharmaceuticals, INC | $41.34 | 2023-2024 | Xarelto |
| Medtronic, INC. | $38.76 | 2023-2025 | Inceptiv, Vanta Adaptivestim |
| Ardelyx, INC. | $36.97 | 2024 | Ibsrela |
| Lexicon Pharmaceuticals, INC. | $36.52 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.19 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $14.65 | 2024 | Airsupra |
| Xeris Pharmaceuticals, INC. | $14.38 | 2025 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kendra Maxey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.